GRI Bio
4 hedge funds and large institutions have $15.5K invested in GRI Bio in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0.03% more ownership
Funds ownership: 0.01% → 0.03% (+0.03%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
43% less funds holding
Funds holding: 7 → 4 (-3)
92% less capital invested
Capital invested by funds: $185K → $15.5K (-$170K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$63.1K |
| 2 |
VF
Virtu Financial
New York
|
-$25K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$19.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$13.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $10.4K | -$19.6K | -78 | -40% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $4.07K | +$9.57K | +38 | +543% |
|
3
BlackRock
New York
| $675 | – | – | – |
|
|
SS
4
SBI Securities
Tokyo,
Japan
| $374 | – | – | – |
|
5
Bank of America
Charlotte,
North Carolina
| $13 | – | – | – |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| – | -$63.1K | -160 | Closed |
|
|
VF
7
Virtu Financial
New York
| – | -$25K | -64 | Closed |
|
|
TSS
8
Two Sigma Securities
New York
| – | -$13.1K | -33 | Closed |
|
GRI Hedge Fund Activity: Q1 2025 in Review
4 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q1 2025, worth a combined $15.5K — down 92% from $185K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GRI and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $9.57K. The largest seller was Geode Capital Management, exiting entirely with an estimated $63.1K sold.
- 4 institutional investors held GRI Bio (GRI) as of Q1 2025, down from 7 in Q4 2024.
- Funds reported $15.5K of GRI Bio stock for Q1 2025, down 92% quarter-over-quarter.
- 0 funds opened new GRI Bio positions in Q1 2025 and 3 closed out, a net change of -3 holders.
- The largest GRI Bio buyer in Q1 2025 was Tower Research Capital (TRC), an estimated $9.57K added.
- The largest GRI Bio seller in Q1 2025 was Geode Capital Management, an estimated $63.1K sold.
Based on aggregated 13F filings for Q1 2025.